Immunova

Executive Summary

Immunova is a Boston-based clinical-stage oncology company leveraging its proprietary Nanolipogel™ nanotechnology platform to develop first-in-class multi-targeted therapies. Founded in 2018, the company aims to precisely deliver drug combinations to the tumor microenvironment, potentially improving patient outcomes compared to conventional approaches. As a Phase 1 private company, Immunova is early in development with no disclosed financials or pipeline details, yet its novel platform could address key challenges in cancer treatment, such as drug resistance and toxicity. The company's focus on combination therapies positions it within the growing trend of multi-targeted oncology treatments, but significant clinical validation is still required.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 safety and efficacy data readout for lead candidate40% success
• H1 2027IND filing for second program using Nanolipogel platform50% success
• 2027Potential partnership or collaboration with larger pharma30% success